The Concept of the Central Strategic Program - Innovative Medicines

Teresa Paszkowska-Reymer 

Abstract

[Abstract body is empty now.]

 

Legal notice
  • Legal notice:

    Copyrighted materials, (c) Pielaszek Research, all rights reserved.
    The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced, stored in or introduced into a retrieval or caching system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), or for any purpose, without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
    In every case, proper references including Author(s) name(s) and URL of this webpage: http://science24.com/paper/15346 must be provided.

 

Related papers
  1. Polimorphism of Active Pharmaceutical Ingredients
  2. CAN A QUEST FOR A NEW DRUG OF POLISH ORIGIN BE SUCCESSFUL?
  3. ROPINIROL - GENERIC DRUG FOR PARKINSON'S DISEASE
  4. SYNTHESIS OF PIOGLITAZONE HYDROCHLORIDE OF PHARMACEUTICAL PURITY AT SMALL PLANT SCALE
  5. NEW IMPROVED METHOD OF POLYMORPHIC α FORM OF IMATINIB MESYLATE (GLEEVEC®) SYNTHESIS.
  6. NEW SYNTHESIS OF 11-(1-PIPERAZINYL)- DIBENZO[b,f][1,4]THIAZEPINE, A CRUCIAL INTERMEDIATE IN QUETIAPINE PRODUCTION.

Presentation: Invited oral at VI Multidyscyplinarna Konferencja Nauki o Leku, by Teresa Paszkowska-Reymer
See On-line Journal of VI Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2008-04-29 22:51
Revised:   2009-06-07 00:48
Google
 
Web science24.com
© 1998-2021 pielaszek research, all rights reserved Powered by the Conference Engine